We’re excited to announce that Sanford-Burnham has signed a licensing agreement with Daiichi Sankyo to further develop a first-in-class small molecule for the treatment of cardiovascular-metabolic disease. The small molecule is based on longstanding, groundbreaking biology work by one of our scientists and his laboratory team, who for decades focused their research on treating a consequence of cardiovascular-metabolic disease. Continue reading “Sanford-Burnham small molecule licensed to Daiichi Sankyo”